SNAPC5 Antibody

What is SNAPC5 and why is it important in molecular biology research?

SNAPC5 (small nuclear RNA activating complex polypeptide 5), also known as SNAP19, is a 19 kDa protein that functions as part of the SNAPc complex. This complex plays a crucial role in the transcription of both RNA polymerase II and III small-nuclear RNA genes . The importance of SNAPC5 in research stems from its involvement in fundamental transcriptional processes. As a subunit of the small nuclear RNA (snRNA)-activating protein complex, it binds to promoters of snRNA genes and recruits other regulatory factors to activate snRNA gene transcription . The protein may specifically play a role in stabilizing the SNAPc complex, making it an important target for studies exploring basic transcriptional regulation.

What applications are SNAPC5 antibodies typically used for?

SNAPC5 antibodies have been validated for multiple research applications with specific recommended protocols:

The antibodies have been particularly useful in cancer research, with documented positive detection in human esophagus cancer and lung cancer tissues . When designing experiments, researchers should note that for IHC applications, antigen retrieval is typically recommended with TE buffer pH 9.0, with citrate buffer pH 6.0 as an alternative option .

How should SNAPC5 antibodies be stored and handled to maintain reactivity?

For optimal performance, SNAPC5 antibodies should be stored at -20°C where they typically remain stable for one year after shipment . The storage buffer generally consists of PBS with 0.02% sodium azide and 50% glycerol pH 7.3 or similar formulations that may include small amounts of preservatives like NaN3 .

Importantly, repeated freeze-thaw cycles should be avoided to maintain antibody integrity. For smaller sized antibody aliquots (e.g., 20µl), manufacturers typically include 0.1% BSA as a stabilizer, and aliquoting is generally unnecessary for -20°C storage of these preparations . When handling the antibody, centrifugation before opening is recommended to ensure complete recovery of vial contents, particularly after shipping or storage .

How can researchers validate the specificity of SNAPC5 antibodies before experimental use?

Validation of SNAPC5 antibody specificity requires a multi-step approach:

First, researchers should conduct a Western blot analysis to confirm the observed molecular weight matches the expected size (approximately 19 kDa for SNAPC5) . For more rigorous validation, CRISPR-Cas9 knockout cell models provide robust controls. This system employs single guide RNA (sgRNA) to direct Cas9 endonuclease to cleave the SNAPC5 gene, creating a true negative control for antibody specificity testing .

The CRISPR-Cas9 validation approach follows this methodological workflow:

• Design and implement CRISPR-Cas9 knockout of SNAPC5 in appropriate cell lines (HeLa cells have shown SNAPC5 expression)

• Confirm knockout efficiency at genomic level (sequencing) and protein level (alternative antibody if available)

• Test SNAPC5 antibody against wild-type vs. knockout cells in intended applications

• Analyze signal difference between samples to determine specificity

This genetic modification approach is considered superior to peptide blocking or immunoprecipitation methods because it eliminates the target protein expression entirely, providing a definitive negative control .

What are the optimal protocols for using SNAPC5 antibodies in immunohistochemistry applications?

For IHC applications with SNAPC5 antibodies, the following optimized protocol is recommended based on validated procedures:

• Tissue preparation: Use formalin-fixed paraffin-embedded (FFPE) tissues sectioned at 3-5 µm thickness.

• Antigen retrieval: Primary recommendation is TE buffer pH 9.0; alternatively, citrate buffer pH 6.0 can be used .

• Blocking: Apply appropriate blocking solution to reduce non-specific binding.

• Primary antibody incubation: Dilute SNAPC5 antibody to 1:20-1:200 (optimization required for each tissue type) .

• Detection: Apply appropriate secondary antibody system and develop according to standard protocols.

The antibody has been successfully tested in diverse human tissues including testis, breast cancer, kidney, esophagus cancer, and lung cancer tissues . When analyzing results, researchers should be aware that SNAPC5 displays predominantly nuclear localization due to its role in transcriptional processes.

What controls should be included when performing Western blot analysis with SNAPC5 antibodies?

A comprehensive Western blot experiment using SNAPC5 antibodies should include the following controls:

• Positive control: HeLa cell lysate has been validated to express detectable levels of SNAPC5 and should be included as a positive control .

• Negative control: Either SNAPC5 knockout cell lines (via CRISPR-Cas9) or cell lines known not to express SNAPC5 should be used as negative controls .

• Loading control: Include antibodies against housekeeping proteins (e.g., GAPDH, β-actin) to normalize protein loading.

• Molecular weight marker: To confirm the observed band corresponds to the expected molecular weight of 19 kDa for SNAPC5 .

The antibody dilution should be optimized within the recommended range of 1:500-1:1000 . Researchers should note that the calculated molecular weight based on amino acid sequence is 8-11 kDa (for 68aa/98aa variants), but the observed molecular weight in Western blots is consistently 19 kDa, likely due to post-translational modifications .

How can SNAPC5 antibodies be utilized in cancer research?

SNAPC5 antibodies have demonstrated utility in cancer research through several methodological approaches:

Immunohistochemical analysis has shown positive detection of SNAPC5 in multiple cancer tissues, including breast cancer, esophagus cancer, and lung cancer . This suggests potential differential expression patterns that might be correlated with disease progression or subtype classification.

For researchers investigating SNAPC5 in cancer contexts, a comprehensive approach should include:

• Expression profiling: Compare SNAPC5 expression levels between normal and malignant tissues, and across cancer stages using IHC with standardized scoring methods.

• Co-localization studies: Combine SNAPC5 immunofluorescence with other transcriptional regulators to investigate potential mechanistic interactions.

• Functional analysis: Use SNAPC5 antibodies to conduct chromatin immunoprecipitation (ChIP) assays to identify SNAPC5-bound genomic regions in cancer vs. normal cell lines.

This approach aligns with methodologies used in previous cancer immunology studies, such as the seromic analysis of antibody responses in non-small cell lung cancer patients .

What are the considerations for using SNAPC5 antibodies in co-immunoprecipitation experiments?

When designing co-immunoprecipitation (Co-IP) experiments to study SNAPC5 interactions with other components of the transcriptional machinery, researchers should consider:

• Antibody selection: Choose SNAPC5 antibodies that have been validated for immunoprecipitation applications. While the current search results don't specifically mention IP validation for the referenced antibodies, researchers should consult additional sources or perform validation tests.

• Buffer conditions: Since SNAPC5 functions within a nuclear protein complex, nuclear extraction protocols are critical. Use buffers that maintain nuclear protein interactions while being compatible with the antibody's performance.

• Cross-linking consideration: Due to potentially transient interactions in transcriptional complexes, consider mild cross-linking with formaldehyde before cell lysis.

• Complex integrity: The SNAPc complex involves multiple protein components, so extraction conditions must be optimized to maintain complex integrity during the Co-IP procedure.

A recommended analytical approach would include Western blot analysis of both input and immunoprecipitated fractions, probing for known SNAPc complex components to confirm successful co-immunoprecipitation of physiologically relevant interaction partners.

How can researchers troubleshoot inconsistent results when using SNAPC5 antibodies across different cell lines?

Inconsistent results across cell lines can arise from multiple sources when working with SNAPC5 antibodies:

• Expression level variation: SNAPC5 expression levels may vary significantly between cell types. Prior to extensive experiments, researchers should first confirm SNAPC5 expression in target cell lines through qRT-PCR.

• Antibody epitope accessibility: The conformation of SNAPC5 may differ across cell types due to varying interaction partners or post-translational modifications. Testing multiple antibodies targeting different epitopes can help address this issue.

• Protocol optimization: Each cell line may require specific lysis conditions, particularly since SNAPC5 is a nuclear protein. Nuclear extraction protocols should be optimized for each cell type.

• Fixation sensitivity: For immunocytochemistry applications, different cell lines may require adjusted fixation procedures to preserve epitope accessibility.

A systematic troubleshooting approach includes titrating antibody concentrations for each cell line, testing various antigen retrieval methods for IHC/ICC applications, and validating results using orthogonal detection methods like mass spectrometry or gene expression analysis.

What are the differences between polyclonal and monoclonal SNAPC5 antibodies in research applications?

When selecting between polyclonal and monoclonal SNAPC5 antibodies, researchers should consider these comparative advantages:

The polyclonal antibodies described in the search results (17272-1-AP and E-AB-19933) have been validated for Western blot, IHC, and immunofluorescence applications . For experiments requiring detection of SNAPC5 in its native conformation within the SNAPc complex, polyclonal antibodies may provide advantages due to their ability to recognize multiple epitopes.

How can SNAPC5 antibodies be validated in multiplexed immunofluorescence protocols?

Validating SNAPC5 antibodies for multiplexed immunofluorescence requires addressing both specificity and compatibility:

• Sequential antibody testing: Prior to multiplexing, each antibody should be tested individually on positive control samples (e.g., HeLa cells for SNAPC5) .

• Cross-reactivity assessment: Test each secondary antibody against all primary antibodies to ensure no cross-reactivity.

• Spectral separation: Ensure fluorophores have sufficient spectral separation to avoid bleed-through.

• Co-localization controls: Include appropriate co-localization controls based on known biology of SNAPC5 (nuclear localization, co-localization with other SNAPc components).

• Signal validation: Use CRISPR-Cas9 knockout controls to validate specificity in the multiplexed context .

For SNAPC5 specifically, researchers should note that its nuclear localization pattern should be maintained in multiplexed protocols. A recommended dilution range of 1:20-1:200 has been established for immunofluorescence applications, but this should be optimized in the context of multiplexed staining .

What considerations should researchers take when using SNAPC5 antibodies for chromatin immunoprecipitation (ChIP) experiments?

While ChIP applications for SNAPC5 antibodies are not specifically mentioned in the provided search results, researchers interested in using these antibodies for ChIP should consider:

• Epitope accessibility: Since SNAPC5 is part of a protein complex that binds DNA, ensure the epitope recognized by the antibody remains accessible when SNAPC5 is bound to chromatin.

• Cross-linking optimization: Optimize formaldehyde cross-linking conditions to preserve protein-DNA interactions while maintaining antibody recognition.

• Sonication parameters: Carefully optimize chromatin fragmentation to yield appropriately sized DNA fragments (typically 200-500 bp).

• Validation controls:

  • Positive control: Include immunoprecipitation with antibodies against known transcription factors or RNA polymerase components

  • Negative control: Use IgG from the same species as the SNAPC5 antibody

  • Specificity control: Include ChIP-qPCR primers for regions known to bind SNAPc complex versus regions not expected to bind

• Downstream analysis: Design ChIP-qPCR primers targeting known or predicted SNAPc binding sites, particularly promoters of snRNA genes.

Given SNAPC5's role in the transcription of snRNA genes, researchers should focus their ChIP-Seq or ChIP-qPCR analysis on promoter regions of these genes to validate successful immunoprecipitation.

How can SNAPC5 antibodies contribute to research on transcriptional regulation mechanisms?

SNAPC5 antibodies can advance research on transcriptional regulation through several methodological approaches:

• Chromatin dynamics: Using SNAPC5 antibodies in combination with other SNAPc component antibodies can help map the assembly dynamics of the SNAPc complex at snRNA gene promoters through sequential ChIP or proximity ligation assays.

• Protein interaction networks: SNAPC5 antibodies can be employed in proximity-dependent biotin identification (BioID) or APEX2 proximity labeling approaches to identify novel interaction partners of SNAPC5 in different cellular contexts.

• Post-translational modifications: Using SNAPC5 antibodies in combination with modification-specific antibodies (phospho, acetyl, etc.) can help determine how SNAPC5 activity is regulated post-translationally.

• Single-cell analysis: SNAPC5 antibodies validated for immunofluorescence can be used in single-cell imaging approaches to study cell-to-cell variability in SNAPc complex assembly and localization.

Since SNAPC5 functions in stabilizing the SNAPc complex , research using these antibodies can particularly illuminate how complex assembly and stability contribute to transcriptional regulation of snRNA genes.

What role can SNAPC5 antibodies play in development of novel diagnostic approaches?

Given the detection of SNAPC5 in various cancer tissues including breast, esophagus, and lung cancers , SNAPC5 antibodies may contribute to diagnostic approaches through:

• Biomarker validation: SNAPC5 antibodies can be used to evaluate whether SNAPC5 expression levels or subcellular localization correlate with disease states or progression, potentially establishing SNAPC5 as a biomarker.

• Multiplex diagnostic panels: Including SNAPC5 antibodies in multiplex IHC panels alongside established diagnostic markers may improve classification accuracy for certain cancer subtypes.

• Circulating antibody detection: Building on methodologies like those described for non-small cell lung cancer , researchers can investigate whether auto-antibodies against SNAPC5 appear in patient sera and correlate with disease.

• Liquid biopsy development: SNAPC5 antibodies could potentially be used to capture SNAPC5-expressing exosomes or circulating tumor cells for minimally invasive diagnostic approaches.

To evaluate diagnostic potential, researchers should conduct retrospective studies correlating SNAPC5 expression (detected by validated antibodies) with clinical outcomes across statistically significant patient cohorts.